BG
ZVRA icon

BlackRock Group’s Zevra Therapeutics ZVRA Stock Holding History

BlackRock Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,556
Closed -$593K – 3051
2016
Q1 		$593K Buy
+2,556
New +$619K ﹤0.01% 2165
2015
Q4 		– Sell
-228
Closed -$71K – 3047
2015
Q3 		$71K Hold
228
– – ﹤0.01% 2785
2015
Q2 		$67K Buy
+228
New +$49.7K ﹤0.01% 2836

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

BlackRock Group's ZVRA Position: Q2 2016 in Review

BlackRock Group sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 2,556 shares — an estimated $593K sold.

BlackRock Group first reported a position in ZVRA in Q2 2015 and held it in 3 quarters. The position peaked at $593K in Q1 2016. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • BlackRock Group reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 2,556 Zevra Therapeutics shares in Q2 2016, an estimated $593K.
  • BlackRock Group first reported a position in Zevra Therapeutics in Q2 2015 and held it in 3 quarters.
  • BlackRock Group's Zevra Therapeutics position peaked at $593K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.